1
|
Rosenberg JE, Powles T, Sonpavde GP, Loriot Y, Duran I, Lee JL, Matsubara N, Vulsteke C, Castellano D, Mamtani R, Wu C, Matsangou M, Campbell M, Petrylak DP. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol 2023; 34:1047-1054. [PMID: 37678672 DOI: 10.1016/j.annonc.2023.08.016] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Revised: 08/24/2023] [Accepted: 08/29/2023] [Indexed: 09/09/2023] Open
Abstract
INTRODUCTION This exploratory analysis evaluated efficacy and safety data for enfortumab vedotin versus chemotherapy over a median follow-up of ∼2 years from EV-301. MATERIALS AND METHODS Patients with locally advanced/metastatic urothelial carcinoma with prior platinum-containing chemotherapy and disease progression during/after programmed cell death protein 1/ligand 1 inhibitor treatment were randomized to enfortumab vedotin or chemotherapy (docetaxel, paclitaxel, vinflunine). Endpoints were overall survival (primary), progression-free survival (PFS), objective response, and safety. RESULTS In total, 608 patients were included (enfortumab vedotin, n = 301; chemotherapy, n = 307). With a median follow-up of 23.75 months, 444 deaths had occurred (enfortumab vedotin, n = 207; chemotherapy, n = 237). Risk of death was reduced by 30% with enfortumab vedotin versus chemotherapy [hazard ratio (HR) 0.70 (95% confidence interval [CI] 0.58-0.85); one-sided, log-rank P = 0.00015]; PFS improved with enfortumab vedotin [HR 0.63 (95% CI 0.53-0.76); one-sided, log-rank P < 0.00001]. Treatment-related adverse event rates were 93.9% for enfortumab vedotin and 91.8% for chemotherapy; grade ≥ 3 event rates were 52.4% and 50.5%, respectively. Grade ≥ 3 treatment-related decreased neutrophil count (14.1% versus 6.1%), decreased white blood cell count (7.2% versus 1.4%), and anemia (7.9% versus 2.7%) were more common with chemotherapy versus enfortumab vedotin; maculopapular rash (7.4% versus 0%), fatigue (6.8% versus 4.5%), and peripheral sensory neuropathy (5.1% versus 2.1%) were more common with enfortumab vedotin. Of special interest adverse events, treatment-related skin reactions occurred in 47.3% of patients receiving enfortumab vedotin and 15.8% of patients receiving chemotherapy; peripheral neuropathy occurred in 48.0% versus 31.6%, respectively, and hyperglycemia in 6.8% versus 0.3%. CONCLUSIONS After a median follow-up of ∼2 years, enfortumab vedotin maintained clinically meaningful overall survival benefit versus chemotherapy, consistent with findings from the EV-301 primary analysis; PFS and overall response benefit remained consistent. Adverse events were manageable; no new safety signals were observed.
Collapse
Affiliation(s)
- J E Rosenberg
- Department of Medicine, Division of Solid Tumor Oncology, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA
| | - T Powles
- Department of Genitourinary Oncology, Barts Cancer Institute, CRUK Experimental Cancer Medicine Centre, London, UK
| | - G P Sonpavde
- Department of Bladder Cancer, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - Y Loriot
- Department of Renal Cancer, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - I Duran
- Department of Medical Oncology, Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain
| | - J-L Lee
- Department of Oncology, Urologic Cancer center, Asan Medical Center and University of Ulsan College of Medicine, Seoul, South Korea
| | - N Matsubara
- Department of Breast and Medical Oncology, National Cancer Center Hospital East, Chiba, Japan
| | - C Vulsteke
- Department of Molecular Imaging - Pathology - Radiotherapy - Oncology, Center for Oncological Research (CORE), University of Antwerp, Integrated Cancer Center Ghent, Ghent, Belgium
| | - D Castellano
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - R Mamtani
- Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia
| | - C Wu
- Department of Biostatistics
| | - M Matsangou
- Department of Therapeutic Area-Oncology, Astellas Pharma, Inc., Northbrook
| | - M Campbell
- Department of Late Stage Development, Seagen Inc., Bothell
| | - D P Petrylak
- Department of Medicine and Urology, Yale Cancer Center, New Haven, USA.
| |
Collapse
|
2
|
Perez-Navarro E, Conteduca V, González-del-Alba A, Mellado B, Cremaschi P, Fernandez-Calvo O, Méndez-Vidal M, Climent M, Duran I, Font A, Fernandez-Perez M, Martínez A, López-Andreo M, Attard G, Castellano D, Grande E, de Giorgi U, Botia J, Palma Méndez J, Gonzalez-Billalabeitia E. Corrigendum to “589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)”. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.01.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
3
|
Loriot Y, Vuillet M, Mamtani R, Rosenberg J, Powles T, Sonpavde G, Duran I, Lee J, Matsubara N, Vulsteke C, Castellano D, Sridhar S, Pappo H, Valderram B, Gurney H, Bedke J, Van der heijden M, Hepp Z, Petrylak D. Qualité de vie et symptômes chez les patients atteints d’un carcinome urothélial localement avancé ou métastatique précédemment traité de l’étude Ev-301 : une étude randomisée de phase 3 comparant enfortumab vedotin à la chimiothérapie. Prog Urol 2021. [DOI: 10.1016/j.purol.2021.08.112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
4
|
Perez Navarro E, Conteduca V, Gonzalez del Alba A, Mellado B, Cremaschi P, Fernandez Calvo O, Mendez Vidal M, Climent Duran M, Duran I, Gallardo Diaz E, Vazquez S, Font Pous A, Gurioli G, Martínez A, López Andreo M, Attard G, Castellano Gauna D, Grande E, Giorgi U, Gonzalez Billalabeitia E. 589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
5
|
Rosenberg J, Powles T, Sonpavde G, Loriot Y, Duran I, Lee J, Matsubara N, Vulsteke C, Castellano D, Mamtani R, Sridhar S, Pappot H, Gurney H, Bedke J, van der Heijden M, Campbell M, Wu C, Matsangou M, Petrylak D. 698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.094] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
6
|
De Velasco G, Alonso-Gordoa T, Rodríguez-Moreno J, Duran I, Carretero-González A, Martin-Soberon M, Gutiérrez Baños J, Guerrero-Ramos F, Dueñas M, Castellano Gauna D. 676P CABOPRE: A phase II study of cabozantinib (cabo) prior cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.072] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
7
|
Vondracek P, Panek R, Hron M, Havlicek J, Weinzettl V, Todd T, Tskhakaya D, Cunningham G, Hacek P, Hromadka J, Junek P, Krbec J, Patel N, Sestak D, Varju J, Adamek J, Balazsova M, Balner V, Barton P, Bielecki J, Bilkova P, Błocki J, Bocian D, Bogar K, Bogar O, Boocz P, Borodkina I, Brooks A, Bohm P, Burant J, Casolari A, Cavalier J, Chappuis P, Dejarnac R, Dimitrova M, Dudak M, Duran I, Ellis R, Entler S, Fang J, Farnik M, Ficker O, Fridrich D, Fukova S, Gerardin J, Hanak I, Havranek A, Herrmann A, Horacek J, Hronova O, Imrisek M, Isernia N, Jaulmes F, Jerab M, Kindl V, Komm M, Kovarik K, Kral M, Kripner L, Macusova E, Majer T, Markovic T, Matveeva E, Mikszuta-Michalik K, Mohelnik M, Mysiura I, Naydenkova D, Nemec I, Ortwein R, Patocka K, Peterka M, Podolnik A, Prochazka F, Prevratil J, Reboun J, Scalera V, Scholz M, Svoboda J, Swierblewski J, Sos M, Tadros M, Titus P, Tomes M, Torres A, Tracz G, Turjanica P, Varavin M, Veselovsky V, Villone F, Wąchal P, Yanovskiy V, Zadvitskiy G, Zajac J, Zak A, Zaloga D, Zelda J, Zhang H. Preliminary design of the COMPASS upgrade tokamak. Fusion Engineering and Design 2021. [DOI: 10.1016/j.fusengdes.2021.112490] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
8
|
Szabados B, Rodriguez-Vida A, Duran I, Crabb S, van der Heijden M, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez M, Suarez C, Linch M, Prendergast A, Tyson C, Mousa K, Castellano D, Powles T. 199O A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.211] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
9
|
Castellano Gauna D, Morales-Barrera R, Duran I, Oh DY, Chung I, Arkenau T, Vaishampayan U, Tuthill M, Borau PG, Shin S, Dang S, Ju CH, Chong E, Lal I, Cole G, Reig Torras O. 754P Ibrutinib (Ibr) in combination with paclitaxel (Pac) has activity in patients (Pts) with advanced urothelial carcinoma (aUC): Final analysis of a phase Ib/II study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
10
|
Gauna DC, Grande E, Duran MC, Lainez N, Duran I, Carrato C, Lobato T, Andrada E, Gonzalez RG, Astudillo L, Estevez SV, Gonzalez BM, Carbonero IG, Quintela ML, Saez M, Billalabeitia EG, Arnau MG, Font A, Malats N, Real F. 759P Towards personalized medicine in MIBC: Immunohistochemistry-based taxonomical classification and outcome in patients treated with adjuvant chemotherapy. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
11
|
Necchi A, Siefker-Radtke A, Loriot Y, Park S, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Zakharia Y, Fu M, Santiago-Walker A, O'Hagan A, Monga M, Tagawa S. 750P Erdafitinib (ERDA) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC): Subgroup analyses of long-term efficacy outcomes of a pivotal phase II trial (BLC2001). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
12
|
Powles T, van der Heijden M, Castellano Gauna D, Loriot Y, Galsky M, Petrylak D, Ogawa O, Park S, Necchi A, Lee JL, De Giorgi U, Bögemann M, Bamias A, Fay A, Duran I, Angra N, Gupta A, He P, Levin W, Bellmunt J. 697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.769] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
13
|
Siefker-Radtke A, Loriot Y, Siena S, Beato C, Duran MC, Varlamov S, Duran I, Tagawa S, Geoffrois L, Mellado B, Semenov A, Delva R, Lykov A, Dirix L, Akapame S, O'Hagan A, Tammaro M, Mosher S, Kang T, Moreno V. 752P Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.824] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
14
|
Petrylak D, Rosenberg J, Lee J, Yonese J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Melhem-Bertrandt A, Powles T. EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz425.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Van der Heijden M, Loriot Y, Duran I, Ravaud A, Retz M, Vogelzang N, Nelson B, Wang J, Shen X, Powles T. Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): A long-term overall survival (OS) and safety update from the phase III IMvigor211 study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz249.017] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Garcia Torralba E, Castellano Gauna D, Sobrevilla N, Guma J, Luengo M, Aparicio J, Sanchez-Muñoz A, Mellado B, Saenz A, Valverde C, Fernández A, Margeli M, Duran I, Fernandez S, Sastre J, Ros S, Maroto P, Aguilar J, Garcia del Muro X, Gonzalez Billalabeitia E. Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz249.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Abstract
ABSTRACTObjectives: Desensitizers contribute to better clinical results by reducing the rate of cervical dentin sensitivity. However, information on their antibacterial effect is limited. This study examined the antibacterial activities of a triclosan containing (Seal & Protect), a benzalconium containing desensitizer (Micro Prime), a fluoride containing prophilaxy paste (Sultan Desensitizer), two fluoride containing varnishes (Cavity Shealth and Ultra EZ), and a dentin bonding primer (All Bond).Methods: The test materials were inserted in the wells of Muller Hinton agar plates inoculated with Streptococcus mutans, Streptococcus salivarious, Staphylococcus aureus, Streptococcus faecalis and Pseudomonas aeruginosa. The diameters of the inhibition zones produced around the materials were measured after 24 h of incubation. The results were analyzed by the Kruskal Wallis one way ANOVA and the Mann-Whitney tests at a significance level of P<.05.Results: Micro Prime Desensitizer containing benzalkonium chloride had the highest antibacterial effectiveness compared to other desensitizers used in this study. In addition, triclosan containing Seal & Protect and acidic components containing All Bond showed very high antibacterial efficacy. On the other hand, fluoride within both varnishes had little antibacterial effectiveness. However a fluoride component in a paste (Sultan Desensitizer) showed very high bactericidal effect.Conclusions: All desensitizers except fluoride varnishes showed various degrees of antibacterial effect against the bacteria tested in this study. If antibacterial effect is also required from the desensitizers’ clinicians should avoid use of varnishes. (Eur J Dent 2008;2:43-47)
Collapse
Affiliation(s)
- Ismet Duran
- Assoc. Prof., Selcuk University, Faculty of Dentistry, Department of Periodontology
| | - Abdulkadir Sengun
- Assoc. Prof., Selcuk University, Faculty of Dentistry, Department of Conservative Dentistry
| | | | - Mustafa Ulker
- Assist. Prof., Erciyes University, Faculty of Dentistry, Deparment of Operative Dentistry
| |
Collapse
|
18
|
Duran I, Paradela C, Caamaño M, Cabanelas P, Tassan-Got L, Audouin L. High-resolution evaluation of the U5(n,f) cross section from 3 keV to 30 keV. EPJ Web Conf 2019. [DOI: 10.1051/epjconf/201921102003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
235U neutron-induced fission cross-section is commonly used as reference for determining other isotope fission cross-section. However, below 150 keV this cross section is only included as Standard at the thermal point and recently its integral value between 7.8 eV and 11 eV [1]. The resolved resonance region, spanning up to 2.25 keV, has been reevaluated with high resolution in the last ENDF/B-VIII release [2] and a SAMMY resonance analysis was done by L. Leal et al. [3] including the CERN-nTOF experimental work of Paradela el al. [4] up to 10 keV, taken into account the IAEA Reference file.
In this work the 235U(n,f) low-background and high-resolution experimental data obtained at the CERN-nTOF facility is combined with previous high-resolution experimental data, in order to produce a very fine grid dataset with normalisation to the IAEA Reference file. The extremelyhigh energy calibration required to reproduce the resonance sharp profiles is based on the nTOF DAQ system with a resolution below 0.1% with reference to the 8.78 eV resonance and to the sharp Al(n,g) capture dip at 5.904 keV.
The comparison of the so-evaluated profile with the experimental data and with the evaluated ones will be discussed.
Collapse
|
19
|
Escudero-Ávila R, Rodríguez-Castaño JD, Osman I, Fernandez F, Medina R, Vargas B, Japón-Rodríguez M, Sancho P, Perez-Valderrama B, Praena-Fernández JM, Duran I. Active surveillance as a successful management strategy for patients with clinical stage I germ cell testicular cancer. Clin Transl Oncol 2018; 21:796-804. [PMID: 30470992 DOI: 10.1007/s12094-018-1990-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2018] [Accepted: 11/10/2018] [Indexed: 11/25/2022]
Abstract
BACKGROUND Cancer-specific survival for patients with clinical stage I (CSI) germ cell testicular cancer (GCTC) is outstanding after inguinal orchidectomy regardless the treatment utilized. This study evaluated whether active surveillance (AS) of such patients yielded similar health outcomes to other therapeutic strategies such as adjuvant chemotherapy, radiotherapy or primary retroperitoneal lymphadenectomy as described in the literature. PATIENTS AND METHODS Patients with CSI GCTC were screened between January 2012 and December 2016. Patients had previously undergone inguinal orchidectomy as the primary treatment and chosen AS as their preferred management strategy after receiving information about all available strategies. RESULTS Out of 91 patients screened, 82 patients selected AS as their preferred management strategy. Relapse rate in the overall population was 20% (95% CI 12-30) and median time to relapse was 11.5 months (range 1.0-35.0). In patients with seminomatous tumors, relapse rate decreased to 13% and median time to relapse was 13 months; whereas in patients with non-seminomatous tumors, relapse rate was 33% (IA) or 29% (IB) and median time to relapse was 12 months in stage IA and 4.5 months in stage IB patients. All relapses were rescued with three or four cycles of chemotherapy and two also required a retroperitoneal lymphadenectomy. All patients are currently alive and free of disease. CONCLUSIONS The clinical outcomes of patients with CSI GCTC managed by AS in this series were excellent. This strategy limited the administration of active treatments specifically to the minority of patients who relapsed without compromising performance.
Collapse
Affiliation(s)
- R Escudero-Ávila
- Medical Oncology Department, Virgen del Rocío University Hospital, Seville, Spain
| | | | - I Osman
- Urology Department, Virgen del Rocío University Hospital, Seville, Spain
| | - F Fernandez
- Medical Oncology Department, Virgen del Rocío University Hospital, Seville, Spain
| | - R Medina
- Urology Department, Virgen del Rocío University Hospital, Seville, Spain
| | - B Vargas
- Radiology Department, Virgen del Rocío University Hospital, Seville, Spain
| | - M Japón-Rodríguez
- Pathology Department, Virgen del Rocío University Hospital, Seville, Spain
| | - P Sancho
- Medical Oncology Department, Virgen del Rocío University Hospital, Seville, Spain
| | - B Perez-Valderrama
- Medical Oncology Department, Virgen del Rocío University Hospital, Seville, Spain
| | - J M Praena-Fernández
- Department of Statistics, FISEVI, Virgen del Rocío University Hospital, Seville, Spain
| | - I Duran
- Medical Oncology Department, Virgen del Rocío University Hospital, Seville, Spain.
- Institute of Biomedicine of Seville (IBIS), CSIC, University of Seville, Seville, Spain.
- Medical Oncology Department, Hospital Universitario Marques de Valdecilla, Avda. Valdecilla s/n, 39008, Santander, Spain.
| |
Collapse
|
20
|
Entler S, Sebek J, Duran I, Vyborny K, Grover O, Kocan M, Vayakis G. High magnetic field test of the ITER outer vessel steady-state magnetic field Hall sensors at ITER relevant temperature. Rev Sci Instrum 2018; 89:10J112. [PMID: 30399944 DOI: 10.1063/1.5038812] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/05/2018] [Accepted: 07/24/2018] [Indexed: 06/08/2023]
Abstract
The ITER outer vessel steady-state magnetic field sensor diagnostics consist of sixty sensor units. Each sensor unit features a pair of ceramic-metal Hall sensors with a sensing layer made of bismuth. The sensors were tested simultaneously in the magnetic field ranging from -12 T to +12 T at the temperature range from 27 to 127 °C. The Hall coefficient and magnetoresistance of the bismuth layer related to the sensors were identified. In the sensor operating conditions, the Hall coefficient dependence on temperature was fitted with an exponential function with a relative error of less than 0.08%, and the dependence on the magnetic field was fitted with a Gaussian-like function with a relative error of less than 0.11%. An alternative expression based on the physical understanding of the free charge carrier transport in semimetals was derived to describe the dependence of the Hall coefficient on the magnetic field, and its fitting error of 1.2 mT in terms of the magnetic field measurement has met the ITER measurement accuracy requirements.
Collapse
Affiliation(s)
- S Entler
- Institute of Plasma Physics of the CAS, Za Slovankou 1782/3, 182 00 Prague 8, Czech Republic
| | - J Sebek
- Institute of Physics of the CAS, Na Slovance 1999/2, 182 21 Prague 8, Czech Republic
| | - I Duran
- Institute of Plasma Physics of the CAS, Za Slovankou 1782/3, 182 00 Prague 8, Czech Republic
| | - K Vyborny
- Institute of Physics of the CAS, Cukrovarnicka 10/112, 162 00 Prague 6, Czech Republic
| | - O Grover
- Institute of Plasma Physics of the CAS, Za Slovankou 1782/3, 182 00 Prague 8, Czech Republic
| | - M Kocan
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, 13067 St. Paul Lez Durance Cedex, France
| | - G Vayakis
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, 13067 St. Paul Lez Durance Cedex, France
| |
Collapse
|
21
|
Puente J, Mendez Vidal M, Saez M, Font Pous A, Duran I, Castellano D, Juan Fita M, Santander C, Arranz Arija J, Sanchez-Hernandez A, Mellado B, Alonso T, Gonzalez del Alba Baamonde M, Maroto P, Lazaro M, Esteban E, Cassinello J, Climent Duran M. Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy284.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
22
|
Petrylak D, Rosenberg J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Melhem-Bertrandt A, Powles T. EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy283.131] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Castellano D, Duran I, Rodríguez-Vida A, Crabb S, van der Heijden M, Font Pous A, Gravis G, Anido Herranz U, Protheroe A, Ravaud A, Maillet D, Mendez-Vidal M, Suarez C, Lorch A, Sternberg C, Linch M, Sarker SJ, Notta J, Mousa K, Powles T. A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy283.108] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Kocan M, Duran I, Entler S, Vayakis G, Agostinetti P, Brombin M, Carmona JM, Gambetta G, Jirman T, Marconato N, Moreau P, Peruzzo S, Spuig P, Walsh M. Steady state magnetic sensors for ITER and beyond: Development and final design (invited). Rev Sci Instrum 2018; 89:10J119. [PMID: 30399664 DOI: 10.1063/1.5038871] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/06/2018] [Accepted: 06/18/2018] [Indexed: 06/08/2023]
Abstract
The measurements of the magnetic field in tokamaks such as ITER and DEMO will be challenging due to the long pulse duration, high neutron flux, and elevated temperatures. The long duration of the plasma pulse makes standard techniques, such as inductive coils, prone to errors. At the same time, the hostile environment, with repairs possible only on blanket exchange, if at all, requires a robust magnetic sensor. This contribution presents the final design of novel, steady-state, magnetic sensors for ITER. A poloidal array of 60 sensors mounted on the vacuum vessel outer shell contributes to the measurement of the plasma current, plasma-wall clearance, low-frequency MHD modes and will allow for crosscheck with the outer-vessel inductive coils. Each sensor hosts a pair of bismuth Hall probes, themselves an outcome of extensive R&D, including neutron irradiations (to 1023 n/m2), temperature cycling tests (73-473 K) and tests at high magnetic field (to 12 T). A significant effort has been devoted to optimize the sensor housing by design and prototyping. The production version features an indium-filled cell for in situ recalibration of the onboard thermocouple, vital for the interpretation of the Hall sensor measurement.
Collapse
Affiliation(s)
- M Kocan
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, 13067 St. Paul Lez Durance Cedex, France
| | - I Duran
- Institute of Plasma Physics of the CAS, Za Slovankou 3, 182 00 Prague, Czech Republic
| | - S Entler
- Institute of Plasma Physics of the CAS, Za Slovankou 3, 182 00 Prague, Czech Republic
| | - G Vayakis
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, 13067 St. Paul Lez Durance Cedex, France
| | - P Agostinetti
- Consorzio RFX, Corso Stati Uniti 4, 35137 Padova, Italy
| | - M Brombin
- Consorzio RFX, Corso Stati Uniti 4, 35137 Padova, Italy
| | - J M Carmona
- AVS, Pol. Ind. Sigma Xixilion Kalea 2, Bajo Pabellón 10, 20870 Elgoibar, Spain
| | - G Gambetta
- Consorzio RFX, Corso Stati Uniti 4, 35137 Padova, Italy
| | - T Jirman
- Department of Physics, Imperial College London, South Kensington Campus, London SW7 2AZ, United Kingdom
| | - N Marconato
- Consorzio RFX, Corso Stati Uniti 4, 35137 Padova, Italy
| | - P Moreau
- CEA, IRFM, F-13108 Saint-Paul-Lez-Durance, France
| | - S Peruzzo
- Consorzio RFX, Corso Stati Uniti 4, 35137 Padova, Italy
| | - P Spuig
- CEA, IRFM, F-13108 Saint-Paul-Lez-Durance, France
| | - M Walsh
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, 13067 St. Paul Lez Durance Cedex, France
| |
Collapse
|
25
|
Damone L, Barbagallo M, Mastromarco M, Mengoni A, Cosentino L, Maugeri E, Heinitz S, Schumann D, Dressler R, Käppeler F, Colonna N, Finocchiaro P, Andrzejewski J, Perkowski J, Gawlik A, Aberle O, Altstadt S, Ayranov M, Audouin L, Bacak M, Balibrea-Correa J, Ballof J, Bécares V, Bečvář F, Beinrucker C, Bellia G, Bernardes AP, Berthoumieux E, Billowes J, Borge MJG, Bosnar D, Brown A, Brugger M, Busso M, Caamaño M, Calviño F, Calviani M, Cano-Ott D, Cardella R, Casanovas A, Castelluccio DM, Catherall R, Cerutti F, Chen YH, Chiaveri E, Correia JGM, Cortés G, Cortés-Giraldo MA, Cristallo S, Diakaki M, Dietz M, Domingo-Pardo C, Dorsival A, Dupont E, Duran I, Fernandez-Dominguez B, Ferrari A, Ferreira P, Furman W, Ganesan S, García-Rios A, Gilardoni S, Glodariu T, Göbel K, Gonçalves IF, González-Romero E, Goodacre TD, Griesmayer E, Guerrero C, Gunsing F, Harada H, Heftrich T, Heyse J, Jenkins DG, Jericha E, Johnston K, Kadi Y, Kalamara A, Katabuchi T, Kavrigin P, Kimura A, Kivel N, Köster U, Kokkoris M, Krtička M, Kurtulgil D, Leal-Cidoncha E, Lederer-Woods C, Leeb H, Lerendegui-Marco J, Lo Meo S, Lonsdale SJ, Losito R, Macina D, Marganiec J, Marsh B, Martínez T, Masi A, Massimi C, Mastinu P, Matteucci F, Mazzone A, Mendoza E, Milazzo PM, Mingrone F, Mirea M, Musumarra A, Negret A, Nolte R, Oprea A, Patronis N, Pavlik A, Piersanti L, Piscopo M, Plompen A, Porras I, Praena J, Quesada JM, Radeck D, Rajeev K, Rauscher T, Reifarth R, Riego-Perez A, Rothe S, Rout P, Rubbia C, Ryan J, Sabaté-Gilarte M, Saxena A, Schell J, Schillebeeckx P, Schmidt S, Sedyshev P, Seiffert C, Smith AG, Sosnin NV, Stamatopoulos A, Stora T, Tagliente G, Tain JL, Tarifeño-Saldivia A, Tassan-Got L, Tsinganis A, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vlachoudis V, Vlastou R, Wallner A, Warren S, Weigand M, Weiß C, Wolf C, Woods PJ, Wright T, Žugec P. ^{7}Be(n,p)^{7}Li Reaction and the Cosmological Lithium Problem: Measurement of the Cross Section in a Wide Energy Range at n_TOF at CERN. Phys Rev Lett 2018; 121:042701. [PMID: 30095928 DOI: 10.1103/physrevlett.121.042701] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Revised: 05/09/2018] [Indexed: 06/08/2023]
Abstract
We report on the measurement of the ^{7}Be(n,p)^{7}Li cross section from thermal to approximately 325 keV neutron energy, performed in the high-flux experimental area (EAR2) of the n_TOF facility at CERN. This reaction plays a key role in the lithium yield of the big bang nucleosynthesis (BBN) for standard cosmology. The only two previous time-of-flight measurements performed on this reaction did not cover the energy window of interest for BBN, and they showed a large discrepancy between each other. The measurement was performed with a Si telescope and a high-purity sample produced by implantation of a ^{7}Be ion beam at the ISOLDE facility at CERN. While a significantly higher cross section is found at low energy, relative to current evaluations, in the region of BBN interest, the present results are consistent with the values inferred from the time-reversal ^{7}Li(p,n)^{7}Be reaction, thus yielding only a relatively minor improvement on the so-called cosmological lithium problem. The relevance of these results on the near-threshold neutron production in the p+^{7}Li reaction is also discussed.
Collapse
Affiliation(s)
- L Damone
- INFN, Sezione di Bari, Italy
- Dipartimento di Fisica, Università degli Studi di Bari, Italy
| | - M Barbagallo
- INFN, Sezione di Bari, Italy
- European Organization for Nuclear Research (CERN), Switzerland
| | - M Mastromarco
- INFN, Sezione di Bari, Italy
- European Organization for Nuclear Research (CERN), Switzerland
| | - A Mengoni
- ENEA, Bologna, Italy
- INFN, Sezione di Bologna, Italy
| | - L Cosentino
- INFN, Laboratori Nazionali del Sud, Catania, Italy
| | - E Maugeri
- Paul Scherrer Institut, Villigen PSI, Switzerland
| | - S Heinitz
- Paul Scherrer Institut, Villigen PSI, Switzerland
| | - D Schumann
- Paul Scherrer Institut, Villigen PSI, Switzerland
| | - R Dressler
- Paul Scherrer Institut, Villigen PSI, Switzerland
| | - F Käppeler
- Karlsruhe Institute of Technology (KIT), Institut für Kernphysik, Karlsruhe, Germany
| | | | | | | | | | - A Gawlik
- Uniwersytet Łódzki, Lodz, Poland
| | - O Aberle
- European Organization for Nuclear Research (CERN), Switzerland
| | - S Altstadt
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - M Ayranov
- European Commission, DG-Energy, Luxembourg
| | - L Audouin
- Centre National de la Recherche Scientifique/IN2P3, IPN, Orsay, France
| | - M Bacak
- European Organization for Nuclear Research (CERN), Switzerland
- Atominstitut der Österreichischen Universitäten, Technische Universität Wien, Austria
| | - J Balibrea-Correa
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - J Ballof
- European Organization for Nuclear Research (CERN), Switzerland
| | - V Bécares
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - F Bečvář
- Charles University, Prague, Czech Republic
| | - C Beinrucker
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - G Bellia
- INFN, Laboratori Nazionali del Sud, Catania, Italy
- Dipartimento di Fisica e Astronomia, Università di Catania, Italy
| | - A P Bernardes
- European Organization for Nuclear Research (CERN), Switzerland
| | | | - J Billowes
- University of Manchester, Oxford Road, Manchester, United Kingdom
| | - M J G Borge
- European Organization for Nuclear Research (CERN), Switzerland
| | - D Bosnar
- Department of Physics, Faculty of Science, University of Zagreb, Croatia
| | - A Brown
- University of York, Heslington, York, United Kingdom
| | - M Brugger
- European Organization for Nuclear Research (CERN), Switzerland
| | - M Busso
- INFN, Sezione di Perugia, Italy
- Dipartimento di Fisica e Geologia, Università di Perugia, Italy
| | - M Caamaño
- Universidade de Santiago de Compostela, Spain
| | - F Calviño
- Universitat Politecnica de Catalunya, Barcelona, Spain
| | - M Calviani
- European Organization for Nuclear Research (CERN), Switzerland
| | - D Cano-Ott
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - R Cardella
- European Organization for Nuclear Research (CERN), Switzerland
- INFN, Laboratori Nazionali del Sud, Catania, Italy
| | - A Casanovas
- Universitat Politecnica de Catalunya, Barcelona, Spain
| | | | - R Catherall
- European Organization for Nuclear Research (CERN), Switzerland
| | - F Cerutti
- European Organization for Nuclear Research (CERN), Switzerland
| | - Y H Chen
- Centre National de la Recherche Scientifique/IN2P3, IPN, Orsay, France
| | - E Chiaveri
- European Organization for Nuclear Research (CERN), Switzerland
| | - J G M Correia
- European Organization for Nuclear Research (CERN), Switzerland
- C2TN, Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Portugal
| | - G Cortés
- Universitat Politecnica de Catalunya, Barcelona, Spain
| | | | - S Cristallo
- INFN, Sezione di Perugia, Italy
- Istituto Nazionale di Astrofisica, Osservatorio Astronomico d'Abruzzo, Italy
| | - M Diakaki
- National Technical University of Athens (NTUA), Greece
| | - M Dietz
- School of Physics and Astronomy, University of Edinburgh, United Kingdom
| | - C Domingo-Pardo
- Instituto de Física Corpuscular, CSIC, Universidad de Valencia, Spain
| | - A Dorsival
- European Organization for Nuclear Research (CERN), Switzerland
| | - E Dupont
- CEA/Saclay, IRFU, Gif-sur-Yvette, France
| | - I Duran
- Universidade de Santiago de Compostela, Spain
| | | | - A Ferrari
- European Organization for Nuclear Research (CERN), Switzerland
| | - P Ferreira
- C2TN, Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Portugal
| | - W Furman
- Joint Institute of Nuclear Research, Dubna, Russia
| | - S Ganesan
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - A García-Rios
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - S Gilardoni
- European Organization for Nuclear Research (CERN), Switzerland
| | - T Glodariu
- Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), Bucharest-Magurele, Romania
| | - K Göbel
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - I F Gonçalves
- C2TN, Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Portugal
| | - E González-Romero
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - T D Goodacre
- European Organization for Nuclear Research (CERN), Switzerland
| | - E Griesmayer
- Atominstitut der Österreichischen Universitäten, Technische Universität Wien, Austria
| | | | - F Gunsing
- CEA/Saclay, IRFU, Gif-sur-Yvette, France
| | - H Harada
- Japan Atomic Energy Agency (JAEA), Tokai-mura, Japan
| | - T Heftrich
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - J Heyse
- European Commission JRC, Institute for Reference Materials and Measurements, Geel, Belgium
| | - D G Jenkins
- University of York, Heslington, York, United Kingdom
| | - E Jericha
- Atominstitut der Österreichischen Universitäten, Technische Universität Wien, Austria
| | - K Johnston
- European Organization for Nuclear Research (CERN), Switzerland
| | - Y Kadi
- European Organization for Nuclear Research (CERN), Switzerland
| | - A Kalamara
- National Technical University of Athens (NTUA), Greece
| | | | - P Kavrigin
- Atominstitut der Österreichischen Universitäten, Technische Universität Wien, Austria
| | - A Kimura
- Japan Atomic Energy Agency (JAEA), Tokai-mura, Japan
| | - N Kivel
- Paul Scherrer Institut, Villigen PSI, Switzerland
| | - U Köster
- Institut Laue-Langevin (ILL), Grenoble, France
| | - M Kokkoris
- National Technical University of Athens (NTUA), Greece
| | - M Krtička
- Charles University, Prague, Czech Republic
| | - D Kurtulgil
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | | | - C Lederer-Woods
- School of Physics and Astronomy, University of Edinburgh, United Kingdom
| | - H Leeb
- Atominstitut der Österreichischen Universitäten, Technische Universität Wien, Austria
| | | | - S Lo Meo
- ENEA, Bologna, Italy
- INFN, Sezione di Bologna, Italy
| | - S J Lonsdale
- School of Physics and Astronomy, University of Edinburgh, United Kingdom
| | - R Losito
- European Organization for Nuclear Research (CERN), Switzerland
| | - D Macina
- European Organization for Nuclear Research (CERN), Switzerland
| | | | - B Marsh
- European Organization for Nuclear Research (CERN), Switzerland
| | - T Martínez
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - A Masi
- European Organization for Nuclear Research (CERN), Switzerland
| | - C Massimi
- INFN, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna, Italy
| | - P Mastinu
- INFN, Laboratori Nazionali di Legnaro, Italy
| | - F Matteucci
- INFN, Sezione di Trieste, Italy
- Dipartimento di Astronomia, Università di Trieste, Italy
| | - A Mazzone
- INFN, Sezione di Bari, Italy
- CNR, IC, Bari, Italy
| | - E Mendoza
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | | | - F Mingrone
- European Organization for Nuclear Research (CERN), Switzerland
| | - M Mirea
- Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), Bucharest-Magurele, Romania
| | - A Musumarra
- INFN, Laboratori Nazionali del Sud, Catania, Italy
- Dipartimento di Fisica e Astronomia, Università di Catania, Italy
| | - A Negret
- Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), Bucharest-Magurele, Romania
| | - R Nolte
- Physikalisch-Technische Bundesanstalt (PTB), Braunschweig, Germany
| | - A Oprea
- Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH), Bucharest-Magurele, Romania
| | | | - A Pavlik
- University of Vienna, Faculty of Physics, Austria
| | - L Piersanti
- INFN, Sezione di Perugia, Italy
- Istituto Nazionale di Astrofisica, Osservatorio Astronomico d'Abruzzo, Italy
| | - M Piscopo
- INFN, Laboratori Nazionali del Sud, Catania, Italy
| | - A Plompen
- European Commission JRC, Institute for Reference Materials and Measurements, Geel, Belgium
| | | | - J Praena
- Universidad de Sevilla, Spain
- Universidad de Granada, Spain
| | | | - D Radeck
- Physikalisch-Technische Bundesanstalt (PTB), Braunschweig, Germany
| | - K Rajeev
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - T Rauscher
- Centre for Astrophysics Research, School of Physics, Astronomy and Mathematics, University of Hertfordshire, Hatfield, United Kingdom
| | - R Reifarth
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - A Riego-Perez
- Universitat Politecnica de Catalunya, Barcelona, Spain
| | - S Rothe
- University of Manchester, Oxford Road, Manchester, United Kingdom
| | - P Rout
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - C Rubbia
- European Organization for Nuclear Research (CERN), Switzerland
| | - J Ryan
- University of Manchester, Oxford Road, Manchester, United Kingdom
| | - M Sabaté-Gilarte
- European Organization for Nuclear Research (CERN), Switzerland
- Universidad de Sevilla, Spain
| | - A Saxena
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - J Schell
- European Organization for Nuclear Research (CERN), Switzerland
- Institute for Materials Science and Center for Nanointegration Duisburg-Essen (CENIDE), University of Duisburg-Essen, Essen, Germany
| | - P Schillebeeckx
- European Commission JRC, Institute for Reference Materials and Measurements, Geel, Belgium
| | - S Schmidt
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - P Sedyshev
- Joint Institute of Nuclear Research, Dubna, Russia
| | - C Seiffert
- European Organization for Nuclear Research (CERN), Switzerland
| | - A G Smith
- University of Manchester, Oxford Road, Manchester, United Kingdom
| | - N V Sosnin
- University of Manchester, Oxford Road, Manchester, United Kingdom
| | | | - T Stora
- European Organization for Nuclear Research (CERN), Switzerland
| | | | - J L Tain
- Instituto de Física Corpuscular, CSIC, Universidad de Valencia, Spain
| | - A Tarifeño-Saldivia
- Universitat Politecnica de Catalunya, Barcelona, Spain
- Instituto de Física Corpuscular, CSIC, Universidad de Valencia, Spain
| | - L Tassan-Got
- Centre National de la Recherche Scientifique/IN2P3, IPN, Orsay, France
| | - A Tsinganis
- European Organization for Nuclear Research (CERN), Switzerland
| | - S Valenta
- Charles University, Prague, Czech Republic
| | - G Vannini
- INFN, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna, Italy
| | | | - P Vaz
- C2TN, Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Portugal
| | | | - V Vlachoudis
- European Organization for Nuclear Research (CERN), Switzerland
| | - R Vlastou
- National Technical University of Athens (NTUA), Greece
| | - A Wallner
- University of Vienna, Faculty of Physics, Austria
- Research School of Physics and Engineering, Australian National University, Canberra, Australia
| | - S Warren
- University of Manchester, Oxford Road, Manchester, United Kingdom
| | - M Weigand
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - C Weiß
- European Organization for Nuclear Research (CERN), Switzerland
| | - C Wolf
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - P J Woods
- School of Physics and Astronomy, University of Edinburgh, United Kingdom
| | - T Wright
- University of Manchester, Oxford Road, Manchester, United Kingdom
| | - P Žugec
- Department of Physics, Faculty of Science, University of Zagreb, Croatia
| |
Collapse
|
26
|
Gunpinar S, Kilic OA, Duran I, Tosun M, Firat T, Soyler G. Evaluation of the Effect of Topical Hypericum perforatum Oil on Excisional Palatal Wound Healing in Rabbits. J INVEST SURG 2018; 33:49-58. [PMID: 29856665 DOI: 10.1080/08941939.2018.1474980] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Aim: The aim of this study was to evaluate the effect of Hypericum perforatum (HP) oil on wound-healing process in rabbit palatal mucosa. Materials and Methods: Thirty-six New Zealand albino rabbits were randomly allocated to following groups; (1) HP oil (test, n = 18) and (2) olive oil (control, n = 18). Palatinal excisional wounds were created and the oils were topically applied (0.1 ml, 30 s, twice a day). Gingival biopsies were excised, and analyzed for re-epithelialization (RE) and granulation tissue maturation (GTM) on days 3, 7, and 14 after surgery. Levels of vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF-2) were assessed using the immunohistochemical method. Apoptotic cells (ACs) were evaluated using TUNEL staining. Enzyme-linked immunosorbent assay was used to assess tissue catalase (CAT) and malondialdehyde (MDA) levels. Results: RE and GTM were completed earlier in the HP oil group than in the control group. The number of positively stained cells/vessels was higher in olive oil than in the test group on day 3 for FGF-2 and on days 3 and 7 for VEGF (p < 0.05). In contrast, on day 14, a higher number of vessels was observed in the HP oil group than in the control group. HP oil treatment reduced the number of ACs compared to olive oil (p < 0.05), but the difference during the healing period did not reach significance. Tissue CAT and MDA levels between groups were not different, and also the results were the same when the levels were analyzed by the evaluated time periods (p > 0.05). Conclusions: The results of this study demonstrated that topical HP oil treatment did not provide an additional benefit to its base, olive oil, in the early phase of secondary wound healing.
Collapse
Affiliation(s)
- Sadiye Gunpinar
- Department of Periodontology, Faculty of Dentistry, Abant Izzet Baysal University, Turkey
| | | | - Ismet Duran
- Private Practice in Periodontology, Konya, Turkey
| | | | - Tulin Firat
- Department of Histology and Embryology, Faculty of Medicine, Abant Izzet Baysal University, Turkey
| | - Gizem Soyler
- Department of Histology and Embryology, Faculty of Medicine, Abant Izzet Baysal University, Turkey
| |
Collapse
|
27
|
Duran I, Martakis K, Hamacher S, Stark C, Semler O, Schoenau E. Are there effects of age, gender, height, and body fat on the functional muscle-bone unit in children and adults? Osteoporos Int 2018; 29:1069-1079. [PMID: 29455248 DOI: 10.1007/s00198-018-4401-4] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2017] [Accepted: 01/17/2018] [Indexed: 01/20/2023]
Abstract
UNLABELLED The aim was to describe the effect of age, gender, height, different stages of human life, and body fat on the functional muscle-bone unit. All these factors had a significant effect on the functional muscle-bone unit and should be addressed when assessing functional muscle-bone unit in children and adults. INTRODUCTION For the clinical evaluation of the functional muscle-bone unit, it was proposed to evaluate the adaptation of the bone to the acting forces. A frequently used parameter for this is the total body less head bone mineral content (TBLH-BMC) determined by dual-energy X-ray absorptiometry (DXA) in relation to the lean body mass (LBM by DXA). LBM correlates highly with muscle mass. Therefore, LBM is a surrogate parameter for the muscular forces acting in everyday life. The aim of the study was to describe the effect of age and gender on the TBLH-BMC for LBM and to evaluate the impact of other factors, such as height, different stages of human life, and of body fat. METHODS As part of the National Health and Nutrition Examination Survey (NHANES) study, between the years 1999-2006 whole-body DXA scans on randomly selected Americans from 8 years of age were carried out. From all eligible DXA scans (1999-2004), three major US ethnic groups were evaluated (non-Hispanic Whites, non-Hispanic Blacks, and Mexican Americans) for further statistical analysis. RESULTS For the statistical analysis, the DXA scans of 8190 non-Hispanic White children and adults (3903 female), of 4931 non-Hispanic Black children and adults (2250 female) and 5421 of Mexican-American children and adults (2424 female) were eligible. Age, gender, body height, and especially body fat had a significant effect on the functional muscle-bone unit. CONCLUSIONS When assessing TBLH-BMC for LBM in children and adults, the effects of age, gender, body fat, and body height should be addressed. These effects were analyzed for the first time in such a large cohort.
Collapse
Affiliation(s)
- I Duran
- Center of Prevention and Rehabilitation, UniReha, University of Cologne, Lindenburger Allee 44, 50931, Cologne, Germany.
| | - K Martakis
- Children's and Adolescents' Hospital, University of Cologne, Cologne, Germany
- Department of International Health, School CAPHRI, Care and Public Health Research Institute, Maastricht University, Maastricht, the Netherlands
| | - S Hamacher
- Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany
| | - C Stark
- Children's and Adolescents' Hospital, University of Cologne, Cologne, Germany
- Cologne Centre for Musculoskeletal Biomechanics, University of Cologne, Cologne, Germany
| | - O Semler
- Children's and Adolescents' Hospital, University of Cologne, Cologne, Germany
- Center for Rare Skeletal Diseases in Childhood, University of Cologne, Cologne, Germany
| | - E Schoenau
- Center of Prevention and Rehabilitation, UniReha, University of Cologne, Lindenburger Allee 44, 50931, Cologne, Germany
- Children's and Adolescents' Hospital, University of Cologne, Cologne, Germany
| |
Collapse
|
28
|
Kocan M, Duran I, Entler S, Vayakis G, Carmona J, Gitton P, Guirao J, Gonzalez M, Iglesias S, Pascual Q, Sandford G, Vacas C, Walsh M, Walton R. Final design of the ITER outer vessel steady-state magnetic sensors. Fusion Engineering and Design 2017. [DOI: 10.1016/j.fusengdes.2017.03.043] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
29
|
Duran I, Lambea J, Maroto P, González-Larriba JL, Flores L, Granados-Principal S, Graupera M, Sáez B, Vivancos A, Casanovas O. Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action. Target Oncol 2017; 12:19-35. [PMID: 27844272 DOI: 10.1007/s11523-016-0463-4] [Citation(s) in RCA: 72] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Renal cell carcinoma (RCC) is a complex disease characterized by mutations in several genes. Loss of function of the von Hippel-Lindau (VHL) tumour suppressor gene is a very common finding in RCC and leads to up-regulation of hypoxia-inducible factor (HIF)-responsive genes accountable for angiogenesis and cell growth, such as platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF). Binding of these proteins to their cognate tyrosine kinase receptors on endothelial cells promotes angiogenesis. Promotion of angiogenesis is in part due to the activation of the phosphatidylinositol-3-kinase (PI3K)/AKT/mechanistic target of rapamycin (mTOR) pathway. Inhibition of this pathway decreases protein translation and inhibits both angiogenesis and tumour cell proliferation. Although tyrosine kinase inhibitors (TKIs) stand as the main first-line treatment option for advanced RCC, eventually all patients will become resistant to TKIs. Resistance can be overcome by using second-line treatments with different mechanisms of action, such as inhibitors of mTOR, c-MET, programmed death 1 (PD-1) receptor, or the combination of an mTOR inhibitor (mTORi) with a TKI. In this article, we briefly review current evidence regarding mechanisms of resistance in RCC and treatment strategies to overcome resistance with a special focus on the PI3K/AKT/mTOR pathway.
Collapse
Affiliation(s)
- I Duran
- Sección de Oncología Médica, Hospital Universitario Virgen del Rocío, Sevilla, Spain.,Laboratorio de Terapias Avanzadas y Biomarcadores en Oncología, Instituto de Biomedicina de Sevilla, Sevilla, Spain
| | - J Lambea
- Servicio de Oncología Médica, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - P Maroto
- Servicio de Oncología Médica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | | | | | - S Granados-Principal
- Servicio de Oncología Médica, Complejo Hospitalario de Jaén, Jaén, Spain.,GENYO, Centre for Genomics and Oncological Research (Pfizer/University of Granada/Andalusian Regional Government), PTS Granada, Granada, Spain
| | - M Graupera
- Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, Barcelona, Spain
| | - B Sáez
- Departmento de Bioquímica, Biología Molecular y Celular, Instituto Universitario de Investigación en Nanociencia de Aragón, Universidad de Zaragoza, Zaragoza, Spain
| | - A Vivancos
- Departamento de Bioquímica y Biología Molecular, Universidad Pompeu Fabra, Barcelona, Spain
| | - O Casanovas
- ProCURE Research Program, Institut Català d'Oncologia-IDIBELL, L'Hospitalet de Llobregat, Avinguda Gran Via, 199-203, 08907, Barcelona, Spain.
| |
Collapse
|
30
|
Duran I, Ventura A, Lo Meo S, Tarrío D, Tassan-Got L, Paradela C. On the search for a (n,f) cross-section reference at intermediate energies. EPJ Web Conf 2017. [DOI: 10.1051/epjconf/201714602032] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Carlson A, Pronyaev V, Hale G, Zhenpeng C, Capote R, Duran I, Hambsch FJ, Kawano T, Kunieda S, Mannhart W, Marcinkevicius B, Nelson R, Neudecker D, Noguere G, Paris M, Schillebeeckx P, Simakov S, Smith D, Talou P, Tao X, Trkov A, Wallner A. A new evaluation of the neutron data standards. EPJ Web Conf 2017. [DOI: 10.1051/epjconf/201714602025] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Dupont E, Otuka N, Cabellos O, Aberle O, Aerts G, Altstadt S, Alvarez H, Alvarez-Velarde F, Andriamonje S, Andrzejewski J, Audouin L, Bacak M, Badurek G, Balibrea J, Barbagallo M, Barros S, Baumann P, Bécares V, Bečvář F, Beinrucker C, Belloni F, Berthier B, Berthoumieux E, Billowes J, Boccone V, Bosnar D, Brown A, Brugger M, Caamaño M, Calviani M, Calviño F, Cano-Ott D, Capote R, Cardella R, Carrapiço C, Casanovas A, Castelluccio D, Cennini P, Cerutti F, Chen Y, Chiaveri E, Chin M, Colonna N, Cortés G, Cortés-Giraldo M, Cosentino L, Couture A, Cox J, Damone L, David S, Deo K, Diakaki M, Dillmann I, Domingo-Pardo C, Dressler R, Dridi W, Duran I, Eleftheriadis C, Embid-Segura M, Fernández-Domínguez B, Ferrant L, Ferrari A, Ferreira P, Finocchiaro P, Fraval K, Frost R, Fujii K, Furman W, Ganesan S, Garcia A, Gawlik A, Gheorghe I, Gilardoni S, Giubrone G, Glodariu T, Göbel K, Gomez-Hornillos M, Goncalves I, Gonzalez-Romero E, Goverdovski A, Gramegna F, Griesmayer E, Guerrero C, Gunsing F, Gurusamy P, Haight R, Harada H, Heftrich T, Heil M, Heinitz S, Hernández-Prieto A, Heyse J, Igashira M, Isaev S, Jenkins D, Jericha E, Kadi Y, Kaeppeler F, Kalamara A, Karadimos D, Karamanis D, Katabuchi T, Kavrigin P, Kerveno M, Ketlerov V, Khryachkov V, Kimura A, Kivel N, Kokkoris M, Konovalov V, Krtička M, Kroll J, Kurtulgil D, Lampoudis C, Langer C, Leal-Cidoncha E, Lederer C, Leeb H, Naour CL, Lerendegui-Marco J, Leong L, Licata M, Meo SL, Lonsdale S, Losito R, Lozano M, Macina D, Manousos A, Marganiec J, Martinez T, Marrone S, Masi A, Massimi C, Mastinu P, Mastromarco M, Matteucci F, Maugeri E, Mazzone A, Mendoza E, Mengoni A, Milazzo P, Mingrone F, Mirea M, Mondelaers W, Montesano S, Moreau C, Mosconi M, Musumarra A, Negret A, Nolte R, O’Brien S, Oprea A, Palomo-Pinto F, Pancin J, Paradela C, Patronis N, Pavlik A, Pavlopoulos P, Perkowski J, Perrot L, Pigni M, Plag R, Plompen A, Plukis L, Poch A, Porras I, Praena J, Pretel C, Quesada J, Radeck D, Rajeev K, Rauscher T, Reifarth R, Riego A, Robles M, Roman F, Rout P, Rudolf G, Rubbia C, Rullhusen P, Ryan J, Sabaté-Gilarte M, Salgado J, Santos C, Sarchiapone L, Sarmento R, Saxena A, Schillebeeckx P, Schmidt S, Schumann D, Sedyshev P, Smith A, Sosnin N, Stamatopoulos A, Stephan C, Suryanarayana S, Tagliente G, Tain J, Tarifeño-Saldivia A, Tarrío D, Tassan-Got L, Tavora L, Terlizzi R, Tsinganis A, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Versaci R, Vermeulen M, Villamarin D, Vicente M, Vlachoudis V, Vlastou R, Voss F, Wallner A, Walter S, Ware T, Warren S, Weigand M, Weiß C, Wolf C, Wiesher M, Wisshak K, Woods P, Wright T, Žugec P. Dissemination of data measured at the CERN n_TOF facility. EPJ Web Conf 2017. [DOI: 10.1051/epjconf/201714607002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Duran I, Martakis K, Stark C, Alberg E, Bossier C, Semler O, Schoenau E. Experience with jumping mechanography in children with cerebral palsy. J Musculoskelet Neuronal Interact 2017; 17:237-245. [PMID: 28860426 PMCID: PMC5601269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVES Jumping mechanography provides robust motor function indicators among healthy children. The aim of the study was to assess the reproducibility and validity of jumping mechanography conducted as single two-legged jump (S2LJ) in children with cerebral palsy (CP). METHODS 215 S2LJ investigations from a sample of 75 children with CP were eligible for evaluation. For the estimation of the reproducibility, only the baseline set of data per patient were used. Gross motor function was evaluated by the Gross Motor Function Measure (GMFM-66). In 135 S2LJ investigations, GMFM-66 was assessed within a week in the same child. This data was used for validity assessment. RESULTS Coefficients of variation for the main outcome parameters ranged between 6.15-9.71%, except for jump height (CV%=27.3%). The intraclass correlation coefficients for peak velocity (Vmax) and peak power relative to body weight (Pmax/mass) was 0.927 and 0.931. Vmax and Pmax/mass were also the test parameters with the strongest correlation to the GMFM-66 score (⟩0.7). CONCLUSIONS S2LJ assessed in the present study provided reproducible outcome measures particularly for Vmax and Pmax/mass in children with CP. Further, Vmax and Pmax/mass showed the strongest correlation with the GMFM-66 score and seem to be the most relevant evaluation criteria.
Collapse
Affiliation(s)
- I. Duran
- University of Cologne, Center of Prevention and Rehabilitation, Germany,Corresponding author: Ibrahim Duran, MD, University of Cologne, Centre of Prevention and Rehabilitation, Lindenburger Allee 44, 50931 Cologne, Germany E-mail:
| | - K. Martakis
- University of Cologne, Children’s and Adolescent’s Hospital, Germany,Maastricht University, Department of International Health, School CAPHRI, Care and Public Health Research Institute, the Netherlands
| | - C. Stark
- University of Cologne, Children’s and Adolescent’s Hospital, Germany,University of Cologne, Cologne Centre for Musculoskeletal Biomechanics (CCMB), Germany
| | - E. Alberg
- University of Cologne, Center of Prevention and Rehabilitation, Germany
| | - C. Bossier
- University of Cologne, Center of Prevention and Rehabilitation, Germany
| | - O. Semler
- University of Cologne, Children’s and Adolescent’s Hospital, Germany,University of Cologne, Center for rare skeletal diseases in childhood, Germany
| | - E. Schoenau
- University of Cologne, Center of Prevention and Rehabilitation, Germany,University of Cologne, Children’s and Adolescent’s Hospital, Germany,University of Cologne, Center for rare skeletal diseases in childhood, Germany
| |
Collapse
|
34
|
Choueiri T, Porta C, Suarez Rodriguez C, Alter R, Czaykowski P, Duran I, Gross-Goupil M, Kalinka-Warzocha E, Melichar B, Patel C, Neuwirth R, Enke A, Zohren F, Powles T. A phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Kα-selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx371.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, Jayaram A, Salvi S, Castellano D, Romanel A, Lolli C, Casadio V, Gurioli G, Amadori D, Font A, Vazquez-Estevez S, González del Alba A, Mellado B, Fernandez-Calvo O, Méndez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez A, Santander C, Sáez MI, Puente J, Gasi Tandefelt D, Wingate A, Dearnaley D, Demichelis F, De Giorgi U, Gonzalez-Billalabeitia E, Attard G. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol 2017; 28:1508-1516. [PMID: 28472366 PMCID: PMC5834043 DOI: 10.1093/annonc/mdx155] [Citation(s) in RCA: 188] [Impact Index Per Article: 26.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC. METHODS We optimized ddPCR assays for AR copy number and mutations and retrospectively analyzed plasma DNA from patients recruited to one of the three biomarker protocols with prospectively collected clinical data. We evaluated associations between plasma AR and overall survival (OS) and progression-free survival (PFS) in 73 chemotherapy-naïve and 98 post-docetaxel CRPC patients treated with enzalutamide or abiraterone (Primary cohort) and 94 chemotherapy-naïve patients treated with enzalutamide (Secondary cohort; PREMIERE trial). RESULTS In the primary cohort, AR gain was observed in 10 (14%) chemotherapy-naïve and 33 (34%) post-docetaxel patients and associated with worse OS [hazard ratio (HR), 3.98; 95% CI 1.74-9.10; P < 0.001 and HR 3.81; 95% CI 2.28-6.37; P < 0.001, respectively], PFS (HR 2.18; 95% CI 1.08-4.39; P = 0.03, and HR 1.95; 95% CI 1.23-3.11; P = 0.01, respectively) and rate of PSA decline ≥50% [odds ratio (OR), 4.7; 95% CI 1.17-19.17; P = 0.035 and OR, 5.0; 95% CI 1.70-14.91; P = 0.003, respectively]. AR mutations [2105T>A (p.L702H) and 2632A>G (p.T878A)] were observed in eight (11%) post-docetaxel but no chemotherapy-naïve abiraterone-treated patients and were also associated with worse OS (HR 3.26; 95% CI 1.47-not reached; P = 0.004). There was no interaction between AR and docetaxel status (P = 0.83 for OS, P = 0.99 for PFS). In the PREMIERE trial, 11 patients (12%) with AR gain had worse PSA-PFS (sPFS) (HR 4.33; 95% CI 1.94-9.68; P < 0.001), radiographic-PFS (rPFS) (HR 8.06; 95% CI 3.26-19.93; P < 0.001) and OS (HR 11.08; 95% CI 2.16-56.95; P = 0.004). Plasma AR was an independent predictor of outcome on multivariable analyses in both cohorts. CONCLUSION Plasma AR status assessment using ddPCR identifies CRPC with worse outcome to enzalutamide or abiraterone. Prospective evaluation of treatment decisions based on plasma AR is now required. CLINICAL TRIAL NUMBER NCT02288936 (PREMIERE trial).
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Androstenes/adverse effects
- Androstenes/therapeutic use
- Antineoplastic Agents, Hormonal/adverse effects
- Antineoplastic Agents, Hormonal/therapeutic use
- Benzamides
- Biomarkers, Tumor/blood
- Biomarkers, Tumor/genetics
- Circulating Tumor DNA/blood
- Circulating Tumor DNA/genetics
- DNA Mutational Analysis
- Disease Progression
- Disease-Free Survival
- Europe
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Multiplex Polymerase Chain Reaction
- Multivariate Analysis
- Mutation
- Nitriles
- Odds Ratio
- Patient Selection
- Phenylthiohydantoin/adverse effects
- Phenylthiohydantoin/analogs & derivatives
- Phenylthiohydantoin/therapeutic use
- Precision Medicine
- Predictive Value of Tests
- Proportional Hazards Models
- Prospective Studies
- Prostatic Neoplasms, Castration-Resistant/blood
- Prostatic Neoplasms, Castration-Resistant/drug therapy
- Prostatic Neoplasms, Castration-Resistant/genetics
- Prostatic Neoplasms, Castration-Resistant/mortality
- Receptors, Androgen/blood
- Receptors, Androgen/genetics
- Risk Factors
- Time Factors
- Treatment Outcome
Collapse
Affiliation(s)
- V. Conteduca
- Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - D. Wetterskog
- Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK
| | - M. T. A. Sharabiani
- Research Data Management and Statistics Unit, The Royal Marsden NHS Foundation Trust, London, UK
| | - E. Grande
- Department of Medical Oncology, Hospital Ramón y Cajal, Madrid
| | - M. P. Fernandez-Perez
- Department of Hematology & Medical Oncology, Hospital Universitario Morales Meseguer, IMIB-Universidad de Murcia, Murcia
| | - A. Jayaram
- Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK
- Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK
| | - S. Salvi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - D. Castellano
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - A. Romanel
- Centre for Integrative Biology, University of Trento, Trento, Italy
| | - C. Lolli
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - V. Casadio
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - G. Gurioli
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - D. Amadori
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - A. Font
- Oncology Unit, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona
| | | | | | - B. Mellado
- Department of Medical Oncology, IDIBAPS Hospital Clinic, Barcelona
| | | | - M. J. Méndez-Vidal
- Department of Medical Oncology, Hospital Universitario Reina Sofía, Córdoba
| | - M. A. Climent
- Department of Medical Oncology, Instituto Valenciano de Oncología Valencia, Valencia
| | - I. Duran
- Department of Medical Oncology, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla
| | - E. Gallardo
- Department of Medical Oncology, H.U. Parc Taulí, Sabadell, Barcelona
| | - A. Rodriguez
- Department of Medical Oncology, Hospital de León, León
| | - C. Santander
- Department of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza
| | - M. I. Sáez
- Department of Medical Oncology, Hospital Regional y Hospital Virgen de la Victoria, Malaga
| | - J. Puente
- Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Spain
| | - D. Gasi Tandefelt
- Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK
| | - A. Wingate
- Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK
| | - D. Dearnaley
- Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK
- Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK
| | | | | | - F. Demichelis
- Centre for Integrative Biology, University of Trento, Trento, Italy
- Institute for Precision Medicine, Weill Cornell Medicine, New York, USA
| | - U. De Giorgi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - E. Gonzalez-Billalabeitia
- Department of Hematology & Medical Oncology, Hospital Universitario Morales Meseguer, IMIB-Universidad de Murcia, Murcia
- Department of Medical Oncology, Universidad Católica San Antonio de Murcia-UCAM, Murcia, Spain
| | - G. Attard
- Centre for Evolution and Cancer, The Institute of Cancer Research, London, UK
- Academic Urology Unit, The Royal Marsden NHS Foundation Trust, London, UK
| |
Collapse
|
36
|
Duran I, Schütz F, Hamacher S, Semler O, Stark C, Schulze J, Rittweger J, Schoenau E. The functional muscle-bone unit in children with cerebral palsy. Osteoporos Int 2017; 28:2081-2093. [PMID: 28365851 DOI: 10.1007/s00198-017-4023-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Accepted: 03/27/2017] [Indexed: 11/24/2022]
Abstract
UNLABELLED Our results suggest that the prevalence of bone health deficits in children with CP was overestimated, when using only age- and height-adjusted bone mineral content (BMC) and areal bone mineral density (aBMD). When applying the functional muscle-bone unit diagnostic algorithm (FMBU-A), the prevalence of positive results decreased significantly. We recommend applying the FMBU-A when assessing bone health in children with CP. INTRODUCTION The prevalence of bone health deficits in children with cerebral palsy (CP) might be overestimated because age- and height-adjusted reference percentiles for bone mineral content (BMC) and areal bone mineral density (aBMD) assessed by dual-energy X-ray absorptiometry (DXA) do not consider reduced muscle activity. The aim of this study was to compare the prevalence of positive DXA-based indicators for bone health deficits in children with CP to the prevalence of positive findings after applying a functional muscle-bone unit diagnostic algorithm (FMBU-A) considering reduced muscle activity. METHODS The present study was a monocentric retrospective analysis of 297 whole body DXA scans of children with CP. The prevalence of positive results of age- and height-adjusted BMC and aBMD defined as BMC and aBMD below the P3 percentile and of the FMBU-A was calculated. RESULTS In children with CP, the prevalence of positive results of age-adjusted BMC were 33.3% and of aBMD 50.8%. Height-adjusted results for BMC and aBMD were positive in 16.8 and 36.0% of cases. The prevalence of positive results applying the FMBU-A regarding BMC and aBMD were significantly (p < 0.001) lower than using age- and height-adjusted BMC and aBMD (8.8 and 14.8%). CONCLUSIONS Our results suggest that the prevalence of bone health deficits in children with CP was overestimated, when using age- and height-adjusted BMC and aBMD. When applying the FMBU-A, the prevalence decreased significantly. We recommend applying the FMBU-A when assessing bone health in children with CP.
Collapse
Affiliation(s)
- I Duran
- Center of Prevention and Rehabilitation, University of Cologne, Lindenburger Allee 44, 50931, Cologne, Germany.
| | - F Schütz
- Center of Prevention and Rehabilitation, University of Cologne, Lindenburger Allee 44, 50931, Cologne, Germany
| | - S Hamacher
- Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany
| | - O Semler
- Center of Prevention and Rehabilitation, University of Cologne, Lindenburger Allee 44, 50931, Cologne, Germany
- Children's Hospital, University of Cologne, Cologne, Germany
- Institute of Aerospace Medicine, German Aerospace Center (DLR), Cologne, Germany
| | - C Stark
- Center of Prevention and Rehabilitation, University of Cologne, Lindenburger Allee 44, 50931, Cologne, Germany
- Children's Hospital, University of Cologne, Cologne, Germany
- Institute of Aerospace Medicine, German Aerospace Center (DLR), Cologne, Germany
| | - J Schulze
- Center of Prevention and Rehabilitation, University of Cologne, Lindenburger Allee 44, 50931, Cologne, Germany
| | - J Rittweger
- Institute of Aerospace Medicine, German Aerospace Center (DLR), Cologne, Germany
| | - E Schoenau
- Center of Prevention and Rehabilitation, University of Cologne, Lindenburger Allee 44, 50931, Cologne, Germany
- Children's Hospital, University of Cologne, Cologne, Germany
- Cologne Center for Musculoskeletal Biomechanics (CCMB), University of Cologne, Cologne, Germany
| |
Collapse
|
37
|
Kovarik K, Duran I, Stockel J, Seidl J, Adamek J, Spolaore M, Vianello N, Hacek P, Hron M, Panek R. Filamentary probe on the COMPASS tokamak. Rev Sci Instrum 2017; 88:035106. [PMID: 28372420 DOI: 10.1063/1.4977591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
This paper describes a new filamentary probe recently introduced on the COMPASS tokamak. It allows the measurement of electrostatic and magnetic properties of the filaments and their changes in dependence on distance from the separatrix in the region between a divertor and midplane. The probe head is mounted on a manipulator moving the probe radially on a shot-to-shot basis. This configuration is suitable for the long term statistical measurement of the plasma filaments and the measurement of their evolution during their propagation from the separatrix to the wall. The basics of the filamentary probe construction, the evolution of the plasma parameters, and first conditional averages of the plasma filaments in the scrape-off layer of the COMPASS tokamak during the L-mode regime are presented.
Collapse
Affiliation(s)
- K Kovarik
- Institute of Plasma Physics of the CAS, Za Slovankou 3, Prague 182 00, Czech Republic
| | - I Duran
- Institute of Plasma Physics of the CAS, Za Slovankou 3, Prague 182 00, Czech Republic
| | - J Stockel
- Institute of Plasma Physics of the CAS, Za Slovankou 3, Prague 182 00, Czech Republic
| | - J Seidl
- Institute of Plasma Physics of the CAS, Za Slovankou 3, Prague 182 00, Czech Republic
| | - J Adamek
- Institute of Plasma Physics of the CAS, Za Slovankou 3, Prague 182 00, Czech Republic
| | - M Spolaore
- Consorzio RFX (CNR, ENEA, INFN, Università di Padova, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - N Vianello
- Consorzio RFX (CNR, ENEA, INFN, Università di Padova, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - P Hacek
- Institute of Plasma Physics of the CAS, Za Slovankou 3, Prague 182 00, Czech Republic
| | - M Hron
- Institute of Plasma Physics of the CAS, Za Slovankou 3, Prague 182 00, Czech Republic
| | - R Panek
- Institute of Plasma Physics of the CAS, Za Slovankou 3, Prague 182 00, Czech Republic
| |
Collapse
|
38
|
Barbagallo M, Musumarra A, Cosentino L, Maugeri E, Heinitz S, Mengoni A, Dressler R, Schumann D, Käppeler F, Colonna N, Finocchiaro P, Ayranov M, Damone L, Kivel N, Aberle O, Altstadt S, Andrzejewski J, Audouin L, Bacak M, Balibrea-Correa J, Barros S, Bécares V, Bečvář F, Beinrucker C, Berthoumieux E, Billowes J, Bosnar D, Brugger M, Caamaño M, Calviani M, Calviño F, Cano-Ott D, Cardella R, Casanovas A, Castelluccio DM, Cerutti F, Chen YH, Chiaveri E, Cortés G, Cortés-Giraldo MA, Cristallo S, Diakaki M, Domingo-Pardo C, Dupont E, Duran I, Fernandez-Dominguez B, Ferrari A, Ferreira P, Furman W, Ganesan S, García-Rios A, Gawlik A, Glodariu T, Göbel K, Gonçalves IF, González-Romero E, Griesmayer E, Guerrero C, Gunsing F, Harada H, Heftrich T, Heyse J, Jenkins DG, Jericha E, Katabuchi T, Kavrigin P, Kimura A, Kokkoris M, Krtička M, Leal-Cidoncha E, Lerendegui J, Lederer C, Leeb H, Lo Meo S, Lonsdale SJ, Losito R, Macina D, Marganiec J, Martínez T, Massimi C, Mastinu P, Mastromarco M, Mazzone A, Mendoza E, Milazzo PM, Mingrone F, Mirea M, Montesano S, Nolte R, Oprea A, Pappalardo A, Patronis N, Pavlik A, Perkowski J, Piscopo M, Plompen A, Porras I, Praena J, Quesada J, Rajeev K, Rauscher T, Reifarth R, Riego-Perez A, Rout P, Rubbia C, Ryan J, Sabate-Gilarte M, Saxena A, Schillebeeckx P, Schmidt S, Sedyshev P, Smith AG, Stamatopoulos A, Tagliente G, Tain JL, Tarifeño-Saldivia A, Tassan-Got L, Tsinganis A, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Vlachoudis V, Vlastou R, Vollaire J, Wallner A, Warren S, Weigand M, Weiß C, Wolf C, Woods PJ, Wright T, Žugec P. ^{7}Be(n,α)^{4}He Reaction and the Cosmological Lithium Problem: Measurement of the Cross Section in a Wide Energy Range at n_TOF at CERN. Phys Rev Lett 2016; 117:152701. [PMID: 27768364 DOI: 10.1103/physrevlett.117.152701] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/22/2016] [Indexed: 06/06/2023]
Abstract
The energy-dependent cross section of the ^{7}Be(n,α)^{4}He reaction, of interest for the so-called cosmological lithium problem in big bang nucleosynthesis, has been measured for the first time from 10 meV to 10 keV neutron energy. The challenges posed by the short half-life of ^{7}Be and by the low reaction cross section have been overcome at n_TOF thanks to an unprecedented combination of the extremely high luminosity and good resolution of the neutron beam in the new experimental area (EAR2) of the n_TOF facility at CERN, the availability of a sufficient amount of chemically pure ^{7}Be, and a specifically designed experimental setup. Coincidences between the two alpha particles have been recorded in two Si-^{7}Be-Si arrays placed directly in the neutron beam. The present results are consistent, at thermal neutron energy, with the only previous measurement performed in the 1960s at a nuclear reactor. The energy dependence reported here clearly indicates the inadequacy of the cross section estimates currently used in BBN calculations. Although new measurements at higher neutron energy may still be needed, the n_TOF results hint at a minor role of this reaction in BBN, leaving the long-standing cosmological lithium problem unsolved.
Collapse
Affiliation(s)
| | - A Musumarra
- Dipartimento di Fisica e Astronomia DFA, Università di Catania, Italy
- INFN-Laboratori Nazionali del Sud, Catania, Italy
| | - L Cosentino
- INFN-Laboratori Nazionali del Sud, Catania, Italy
| | - E Maugeri
- Paul Scherrer Institut, 5232 Villigen PSI, Switzerland
| | - S Heinitz
- Paul Scherrer Institut, 5232 Villigen PSI, Switzerland
| | | | - R Dressler
- Paul Scherrer Institut, 5232 Villigen PSI, Switzerland
| | - D Schumann
- Paul Scherrer Institut, 5232 Villigen PSI, Switzerland
| | - F Käppeler
- Karlsruhe Institute of Technology (KIT), Institut für Kernphysik, Karlsruhe, Germany
| | | | | | - M Ayranov
- European Commission, DG-Energy, Luxembourg
| | | | - N Kivel
- Paul Scherrer Institut, 5232 Villigen PSI, Switzerland
| | | | - S Altstadt
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | | | - L Audouin
- Centre National de la Recherche Scientifique/IN2P3-IPN, Orsay, France
| | - M Bacak
- Atominstitut der Österreichischen Universitäten, Technische Universität Wien, Austria
| | - J Balibrea-Correa
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - S Barros
- C2TN-Instituto Superior Tecníco, Universidade de Lisboa, Portugal
| | - V Bécares
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - F Bečvář
- Charles University, Prague, Czech Republic
| | - C Beinrucker
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | | | - J Billowes
- University of Manchester, Oxford Road, Manchester, United Kingdom
| | - D Bosnar
- Department of Physics, Faculty of Science, University of Zagreb, Croatia
| | | | - M Caamaño
- Universidade de Santiago de Compostela, Spain
| | | | - F Calviño
- Universitat Politecnica de Catalunya, Barcelona, Spain
| | - D Cano-Ott
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - R Cardella
- INFN-Laboratori Nazionali del Sud, Catania, Italy
- CERN, Geneva, Switzerland
| | - A Casanovas
- Universitat Politecnica de Catalunya, Barcelona, Spain
| | | | | | - Y H Chen
- Centre National de la Recherche Scientifique/IN2P3-IPN, Orsay, France
| | | | - G Cortés
- Universitat Politecnica de Catalunya, Barcelona, Spain
| | | | - S Cristallo
- INAF-Osservatorio Astronomico di Collurania, Teramo, Italy
| | - M Diakaki
- National Technical University of Athens (NTUA), Greece
| | - C Domingo-Pardo
- Instituto de Física Corpuscular, CSIC-Universidad de Valencia, Spain
| | - E Dupont
- CEA/Saclay-IRFU, Gif-sur-Yvette, France
| | - I Duran
- Universidade de Santiago de Compostela, Spain
| | | | | | - P Ferreira
- C2TN-Instituto Superior Tecníco, Universidade de Lisboa, Portugal
| | - W Furman
- Joint Institute of Nuclear Research, Dubna, Russia
| | - S Ganesan
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - A García-Rios
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - A Gawlik
- Uniwersytet Łódzki, Lodz, Poland
| | - T Glodariu
- Horia Hulubei National Institute of Physics and Nuclear Engineering-IFIN HH, Bucharest-Magurele, Romania
| | - K Göbel
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - I F Gonçalves
- C2TN-Instituto Superior Tecníco, Universidade de Lisboa, Portugal
| | - E González-Romero
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - E Griesmayer
- Atominstitut der Österreichischen Universitäten, Technische Universität Wien, Austria
| | | | - F Gunsing
- CEA/Saclay-IRFU, Gif-sur-Yvette, France
| | - H Harada
- Japan Atomic Energy Agency (JAEA), Tokai-mura, Japan
| | - T Heftrich
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - J Heyse
- European Commission JRC, Institute for Reference Materials and Measurements, Retieseweg 111, B-2440 Geel, Belgium
| | - D G Jenkins
- University of York, Heslington, York, United Kingdom
| | - E Jericha
- Atominstitut der Österreichischen Universitäten, Technische Universität Wien, Austria
| | | | - P Kavrigin
- Atominstitut der Österreichischen Universitäten, Technische Universität Wien, Austria
| | - A Kimura
- Japan Atomic Energy Agency (JAEA), Tokai-mura, Japan
| | - M Kokkoris
- National Technical University of Athens (NTUA), Greece
| | - M Krtička
- Charles University, Prague, Czech Republic
| | | | | | - C Lederer
- School of Physics and Astronomy, University of Edinburgh, United Kingdom
| | - H Leeb
- Atominstitut der Österreichischen Universitäten, Technis che Universität Wien, Austria
| | - S Lo Meo
- ENEA, Bologna, Italy
- INFN, Sezione di Bologna, Italy
| | - S J Lonsdale
- School of Physics and Astronomy, University of Edinburgh, United Kingdom
| | | | | | | | - T Martínez
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | - C Massimi
- INFN, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna
| | - P Mastinu
- INFN-Laboratori Nazionali di Legnaro, Italy
| | | | - A Mazzone
- INFN, Sezione di Bari, Italy
- CNR-IC, Bari, Italy
| | - E Mendoza
- Centro de Investigaciones Energeticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
| | | | - F Mingrone
- INFN, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna
| | - M Mirea
- Horia Hulubei National Institute of Physics and Nuclear Engineering-IFIN HH, Bucharest-Magurele, Romania
| | | | - R Nolte
- Physikalisch Technische Bundesanstalt (PTB), Braunschweig, Germany
| | - A Oprea
- Horia Hulubei National Institute of Physics and Nuclear Engineering-IFIN HH, Bucharest-Magurele, Romania
| | - A Pappalardo
- INFN-Laboratori Nazionali del Sud, Catania, Italy
| | | | - A Pavlik
- University of Vienna, Faculty of Physics, Austria
| | | | - M Piscopo
- INFN-Laboratori Nazionali del Sud, Catania, Italy
| | - A Plompen
- European Commission JRC, Institute for Reference Materials and Measurements, Retieseweg 111, B-2440 Geel, Belgium
| | | | - J Praena
- Universidad de Sevilla, Spain
- Universidad de Granada, Spain
| | | | - K Rajeev
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - T Rauscher
- Centre for Astrophysics Research, School of Physics, Astronomy and Mathematics, University of Hertfordshire, Hatfield, United Kingdom
- Department of Physics, University of Basel, Basel, Switzerland
| | - R Reifarth
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - A Riego-Perez
- Universitat Politecnica de Catalunya, Barcelona, Spain
| | - P Rout
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | | | - J Ryan
- University of Manchester, Oxford Road, Manchester, United Kingdom
| | | | - A Saxena
- Bhabha Atomic Research Centre (BARC), Mumbai, India
| | - P Schillebeeckx
- European Commission JRC, Institute for Reference Materials and Measurements, Retieseweg 111, B-2440 Geel, Belgium
| | - S Schmidt
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - P Sedyshev
- Joint Institute of Nuclear Research, Dubna, Russia
| | - A G Smith
- University of Manchester, Oxford Road, Manchester, United Kingdom
| | | | | | - J L Tain
- Instituto de Física Corpuscular, CSIC-Universidad de Valencia, Spain
| | | | - L Tassan-Got
- Centre National de la Recherche Scientifique/IN2P3-IPN, Orsay, France
| | | | - S Valenta
- Charles University, Prague, Czech Republic
| | - G Vannini
- INFN, Sezione di Bologna, Italy
- Dipartimento di Fisica e Astronomia, Università di Bologna
| | | | - P Vaz
- C2TN-Instituto Superior Tecníco, Universidade de Lisboa, Portugal
| | | | | | - R Vlastou
- National Technical University of Athens (NTUA), Greece
| | | | - A Wallner
- University of Vienna, Faculty of Physics, Austria
- Research School of Physics and Engineering, Australian National University, ACT 0200, Australia
| | - S Warren
- University of Manchester, Oxford Road, Manchester, United Kingdom
| | - M Weigand
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - C Weiß
- CERN, Geneva, Switzerland
| | - C Wolf
- Johann-Wolfgang-Goethe Universität, Frankfurt, Germany
| | - P J Woods
- School of Physics and Astronomy, University of Edinburgh, United Kingdom
| | - T Wright
- University of Manchester, Oxford Road, Manchester, United Kingdom
| | - P Žugec
- Department of Physics, Faculty of Science, University of Zagreb, Croatia
| |
Collapse
|
39
|
Anido U, Fita MJ, Munielo-Romay L, Pérez-Valderrama B, Mellado B, de Olza MO, Calvo OF, Castellano D, Parra EF, Domenec M, Hernando S, Arija JA, Caballero C, Duran I, Campayo M, Climent M. Phase II study of weekly cabazitaxel for ‘unfit’ metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. Circulating tumour cell (CTC) analysis (SOGUG-CABASEM Trial). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw372.37] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
Tannir N, Powles T, Motzer R, Rolland F, Gravis G, Staehler M, Rink M, Retz M, Csoszi T, McCaffrey J, De Giorgi U, Caserta C, Cheporov S, Esteban Gonzalez E, Duran I, Larkin J, Berg W, Clary D, Escudier B, Choueiri T. Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw373.45] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Garcia-Carbonero R, Boni V, Duran I, Gil M, Espinosa M, Salazar R, Cubillo A, Jurado M, Champion B, Alvis S, Fisher K, Beadle J, Pover G, McElwaine-Johnn H, Ellis C, Blanc C, Calvo E. A mechanism of action study of intra-tumoral or intravenous dosing of enadenotucirev, an oncolytic adenovirus in patients with colon, lung, bladder and renal carcinoma undergoing resection of primary tumor. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw378.41] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Grande E, Fernández Pérez M, Font A, Vazquez S, Mellado B, Fernandez Calvo O, Méndez Vidal M, Climent M, González del Alba A, Gallardo E, Rodríguez Sánchez A, Santander C, Sáez M, Duran I, Puente J, Alonso Gordoa T, Tudela J, Martínez A, Castellano D, González Billalabeitia E. Early responses to enzalutamide in AR-V7 positive first line metastatic castration-resistant prostate cancer (mCRPC). A prospective SOGUG clinical trial: The PREMIERE study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw372.10] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Loriot Y, Rosenberg J, Powles T, Necchi A, Hussain S, Morales R, Retz M, Niegisch G, Duran I, Theodore C, Perez-Gracia J, Grande Pulido E, Thåström A, Danner B, Mariathasan S, Abidoye O, van der Heijden M. Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw373.11] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Stark C, Herkenrath P, Hollmann H, Waltz S, Becker I, Hoebing L, Semler O, Hoyer-Kuhn H, Duran I, Hero B, Hadders-Algra M, Schoenau E. Early vibration assisted physiotherapy in toddlers with cerebral palsy - a randomized controlled pilot trial. J Musculoskelet Neuronal Interact 2016; 16:183-92. [PMID: 27609033 PMCID: PMC5114341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVES to investigate feasibility, safety and efficacy of home-based side-alternating whole body vibration (sWBV) to improve motor function in toddlers with cerebral palsy (CP). METHODS Randomized controlled trial including 24 toddlers with CP (mean age 19 months (SD±3.1); 13 boys). INTERVENTION 14 weeks sWBV with ten 9-minute sessions weekly (non-individualized). Group A started with sWBV, followed by 14 weeks without; in group B this order was reversed. Feasibility (≥70% adherence) and adverse events were recorded; efficacy evaluated with the Gross Motor Function Measure (GMFM-66), Pediatric Evaluation of Disability Inventory (PEDI), at baseline (T0), 14 (T1) and 28 weeks (T2). RESULTS Developmental change between T0 and T1 was similar in both groups; change scores in group A and B: GMFM-66 2.4 (SD±2.1) and 3.3 (SD±2.9) (p=0.412); PEDI mobility 8.4 (SD±6.6) and 3.5 (SD±9.2) (p=0.148), respectively. In two children muscle tone increased post-sWBV. 24 children received between 67 and 140 sWBV sessions, rate of completed sessions ranged from 48 to 100% and no dropouts were observed. CONCLUSION A 14-week home-based sWBV intervention was feasible and safe in toddlers with CP, but was not associated with improvement in gross motor function.
Collapse
Affiliation(s)
- C. Stark
- University of Cologne, Children’s Hospital, Germany,University of Cologne, Cologne Centre for Musculoskeletal Biomechanics (CCMB), Germany,Corresponding author: Christina Stark, PT, M.Sc., Children’s Hospital, University of Cologne, Kerpener Str. 62, 50939 Köln, Germany E-mail:
| | - P. Herkenrath
- University of Cologne, Department of Neuropediatrics, Germany
| | - H. Hollmann
- LVR-Clinics Bonn, Centre of Child Neurology, Germany
| | - S. Waltz
- Clinics of the City of Cologne, Children’s Hospital, Germany
| | - I. Becker
- University of Cologne, Institute of Medical Statistics, Informatics and Epidemiology (IMSIE), Germany
| | - L. Hoebing
- University of Cologne, Children’s Hospital, Germany
| | - O. Semler
- University of Cologne, Children’s Hospital, Germany,University of Cologne, Cologne Centre for Musculoskeletal Biomechanics (CCMB), Germany
| | | | - I. Duran
- UniReha GmbH, Pediatric Rehabilitation Centre, Germany
| | - B. Hero
- University of Cologne, Children’s Hospital, Germany
| | - M. Hadders-Algra
- University of Groningen, University Medical Center Groningen (UMCG), Department of Pediatrics - Div. Developmental Neurology, Netherlands
| | - E. Schoenau
- University of Cologne, Children’s Hospital, Germany,University of Cologne, Cologne Centre for Musculoskeletal Biomechanics (CCMB), Germany,UniReha GmbH, Pediatric Rehabilitation Centre, Germany
| |
Collapse
|
45
|
Kempf E, Desamericq G, Vieites B, Diaz-Padilla I, Calvo E, Estevez P, Garcia-Arreza A, Martinez-Maestre MA, Duran I. Clinical and pathologic features of patients with non-epithelial ovarian cancer: retrospective analysis of a single institution 15-year experience. Clin Transl Oncol 2016; 19:173-179. [PMID: 27193130 DOI: 10.1007/s12094-016-1517-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2016] [Accepted: 04/30/2016] [Indexed: 11/28/2022]
Abstract
PURPOSE Non-epithelial ovarian cancers (NEOCs) are rare diseases. Despite their overall good prognosis, the best management and current prognostic factors remain unclear. The objective of our study was to assess the clinical and pathological features of NEOC patients treated in our institution in the last 15 years and to explore risk factors for relapse and survival. METHODS/PATIENTS All patients with a pathological diagnosis of NEOC referred to the medical oncology department at Hospital Universitario Virgen del Rocio between 1999 and 2014 were included. Demographics, tumor characteristics, treatment procedures, and clinical follow-up were retrospectively collected. Risk factors for disease-free survival (DFS) and overall survival (OS) were assessed. RESULTS Fifty-seven patients were included, 33 (58 %) had a sex cord-stromal tumor (SCST) and 24 (42 %) had a germ-cell tumor (GCT). Median age, non-conservative surgery rates and DFS were lower in the GCT cohort; however, salvage chemotherapy led to a high proportion of complete responses in this group translating into a 90 % 3-year OS rate in both NEOC subtypes. The only identified risk factors statistically significant were stage and tumour relapse that associated, respectively, with DFS (HR = 8.84; 95 % CI 1.85-42) and OS (HR = 11.02; 95 % CI 1.76-68.7). CONCLUSIONS Despite their rarity, NEOCs remain a highly curable group of neoplasm. In our series, a more conservative treatment approach in ovarian GCTs revealed comparable OS outcomes to SCST. No new risk factors that would help in patient stratification were identified.
Collapse
Affiliation(s)
- E Kempf
- Medical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain.,Medical Oncology Department, AP-HP, H. Mondor-A. Chenevier Hospital, Créteil, France
| | - G Desamericq
- Centre de Référence Maladie de Huntington, AP-HP, Hôpital H. Mondor-A. Chenevier, Créteil, France.,Inserm, U955, Equipe 01, Créteil, France.,Faculté de Médecine, Université Paris Est, Créteil, France.,Département d'Etudes Cognitives, Ecole Normale Supérieure, Paris, France
| | - B Vieites
- Department of Pathology, Hospital Universitario Virgen del Rocio, Seville, Spain
| | - I Diaz-Padilla
- Deanery of Doctorate Studies, School of Medicine, University of Seville, Seville, Spain
| | - E Calvo
- Medical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain
| | - P Estevez
- Medical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain
| | - A Garcia-Arreza
- Gynecology Department, Hospital Universitario Virgen del Rocio, Seville, Spain
| | | | - I Duran
- Medical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain. .,Instituto de Biomedicina de Sevilla (IBIS), Seville, Spain.
| |
Collapse
|
46
|
Diakaki M, Audouin L, Berthoumieux E, Calviani M, Colonna N, Dupont E, Duran I, Gunsing F, Leal-Cidoncha E, Le Naour C, Leong L, Mastromarco M, Paradela C, Tarrio D, Tassan-Got L, Aerts G, Altstadt S, Alvarez H, Alvarez-Velarde F, Andriamonje S, Andrzejewski J, Badurek G, Barbagallo M, Baumann P, Becares V, Becvar F, Belloni F, Berthier B, Billowes J, Boccone V, Bosnar D, Brugger M, Calvino F, Cano-Ott D, Capote R, Carrapiço C, Cennini P, Cerutti F, Chiaveri E, Chin M, Cortes G, Cortes-Giraldo M, Cosentino L, Couture A, Cox J, David S, Dillmann I, Domingo-Pardo C, Dressler R, Dridi W, Eleftheriadis C, Embid-Segura M, Ferrant L, Ferrari A, Finocchiaro P, Fraval K, Fujii K, Furman W, Ganesan S, Garcia A, Giubrone G, Gomez-Hornillos M, Goncalves I, Gonzalez-Romero E, Goverdovski A, Gramegna F, Griesmayer E, Guerrero C, Gurusamy P, Haight R, Heil M, Heinitz S, Igashira M, Isaev S, Jenkins D, Jericha E, Kadi Y, Kaeppeler F, Karadimos D, Karamanis D, Kerveno M, Ketlerov V, Kivel N, Kokkoris M, Konovalov V, Krticka M, Kroll J, Lampoudis C, Langer C, Lederer C, Leeb H, Lo Meo S, Losito R, Lozano M, Manousos A, Marganiec J, Martinez T, Marrone S, Massimi C, Mastinu P, Mendoza E, Mengoni A, Milazzo P, Mingrone F, Mirea M, Mondelaers W, Moreau C, Mosconi M, Musumarra A, O’Brien S, Pancin J, Patronis N, Pavlik A, Pavlopoulos P, Perkowski J, Perrot L, Pigni M, Plag R, Plompen A, Plukis L, Poch A, Pretel C, Praena J, Quesada J, Rauscher T, Reifarth R, Riego A, Roman F, Rudolf G, Rubbia C, Rullhusen P, Salgado J, Santos C, Sarchiapone L, Sarmento R, Saxena A, Schillebeeckx P, Schmidt S, Schumann D, Stephan C, Tagliente G, Tain J, Tavora L, Terlizzi R, Tsinganis A, Valenta S, Vannini G, Variale V, Vaz P, Ventura A, Versaci R, Vermeulen M, Villamarin D, Vincente M, Vlachoudis V, Vlastou R, Voss F, Wallner A, Walter S, Ware T, Weigand M, Weiß C, Wiesher M, Wisshak K, Wright T, Zugec P. Towards the high-accuracy determination of the238U fission cross section at the threshold region at CERN – n_TOF. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201611102002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Paradela C, Duran I, Tassan-Got L, Audouin L, Berthier B, Isaev S, Le Naour C, Stephan C, Tarrío D, Abbondanno U, Aerts G, Álvarez-Pol H, Álvarez-Velarde F, Andriamonje S, Andrzejewski J, Badurek G, Baumann P, Becvar F, Berthoumieux E, Calviño F, Calviani M, Cano-Ott D, Capote R, Carrapiço C, Cennini P, Chepel V, Chiaveri E, Colonna N, Cortes G, Couture A, Cox J, Dahlfors M, David S, Dillmann I, Domingo-Pardo C, Dridi W, Eleftheriadis C, Embid-Segura M, Ferrant L, Ferrari A, Ferreira-Marques R, Fujii K, Furman W, Gonçalves I, Gonzalez-Romero E, Goverdovski A, Gramegna F, Guerrero C, Gunsing F, Haight R, Heil M, Igashira M, Jericha E, Kadi Y, Kaeppeler F, Karadimos D, Kerveno M, Ketlerov V, Koehler P, Konovalov V, Krticka M, Lampoudis C, Lederer C, Leeb H, Lindote A, Lukic S, Marganiec J, Martinez T, Marrone S, Massimi C, Mastinu P, Mengoni A, Milazzo P, Moreau C, Mosconi M, Pancin SJ, Pavlik A, Pavlopoulos P, Perrot L, Plag R, Plompen A, Plukis A, Poch A, Pretel C, Praena J, Quesada J, Rauscher T, Reifarth R, Rubbia C, Rudolf G, Rullhusen P, Salgado J, Santos C, Sarchiapone L, Savvidis I, Tagliente G, Tain J, Tavora L, Terlizzi R, Vaz P, Ventura A, Villamarin D, Vincente M, Vlachoudis V, Vlastou R, Voss F, Walter S, Weiss C, Wiesher M, Wisshak K. High accuracy235U(n,f) data in the resonance energy region. EPJ Web of Conferences 2016. [DOI: 10.1051/epjconf/201611102003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Duran I, Fink M, Bahl A, Hoefeler H, Mahmood A, Lüftner D, Ghazal H, Wei R, Chung K, Hechmati G, Green J, Atchison C. Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study. Eur J Cancer Care (Engl) 2016; 26. [DOI: 10.1111/ecc.12452] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/29/2015] [Indexed: 12/25/2022]
Affiliation(s)
- I. Duran
- Medical Oncology Department; Centro Integral Oncologico Clara Campal; Madrid Spain
| | - M.G. Fink
- Orange Coast Memorial Medical Center; Fountain Valley CA USA
| | - A. Bahl
- Bristol Haematology and Oncology Centre; University Hospitals Bristol; Bristol UK
| | - H. Hoefeler
- Forschungszentrum Ruhr; KliFoCenter GmbH; Witten Germany
| | - A. Mahmood
- Cancer Specialists of South Texas; Corpus Christi Cancer Center; Corpus Christi TX USA
| | - D. Lüftner
- Universitätsmedizin Berlin; Charité Campus Benjamin Franklin; Berlin Germany
| | | | - R. Wei
- Biostatistics; Amgen, Inc.; Thousand Oaks CA
| | - K.C. Chung
- Global Health Economics; Amgen Inc.; Thousand Oaks CA USA
| | - G. Hechmati
- Global Health Economics; Amgen Inc.; Zug Switzerland
| | - J. Green
- Global Study Management; Amgen Inc.; Thousand Oaks CA
| | - C. Atchison
- Global Health Economics; Amgen Inc.; Thousand Oaks CA USA
| |
Collapse
|
49
|
Duran I, Csukasi F, Taylor S, Krakow D, Becerra J, Bombarely A, Marí-Beffa M. Collagen duplicate genes of bone and cartilage participate during regeneration of zebrafish fin skeleton. Gene Expr Patterns 2015; 19:60-9. [DOI: 10.1016/j.gep.2015.07.004] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Revised: 07/14/2015] [Accepted: 07/31/2015] [Indexed: 11/17/2022]
|
50
|
Duran I, Yilmaz B, Tatar N, Ural C, Güler AU. Determining the localization of premolar zenith positions according to the gingival line. Niger J Clin Pract 2015; 18:273-5. [PMID: 25666006 DOI: 10.4103/1119-3077.151066] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND The gingival zenith (GZ) positions according to a reference line in the premolar (PM) area remain concern, especially for the clinicians in placing the gingival contours during surgery. OBJECTIVES The objectives of this study are to determine the maxillary PM GZ positions according to GZ line (GZL). MATERIALS AND METHODS A sample population of 63 patients with healthy gingival tissue was studied. The GZ was determined at the most apical point of the gingival marginal scallop. A horizontal-zenith line (ZL) was drawn connecting the GZ from the ipsilateral canine (C) and central incisor teeth. Reference lines were drawn, and bilateral measurements were taken in the respective stone casts in the PM area. RESULTS No statistically significant differences were found between bilateral first premolars (FPM) and second premolars (SPM). When considering ipsilateral FPM and SPM, statistically significant differences were found between them. For all PM teeth, the mean distance value of GZ to GZL was approximately 1.32 mm. CONCLUSIONS The present study results showed that GZs of FPM and SPM teeth for both left and right sight was coronally located according to ZL.
Collapse
Affiliation(s)
| | | | | | - C Ural
- Department of Prosthodontics, Ondokuz Mayis University, Faculty of Dentistry, Atakum, Samsun, Turkey
| | | |
Collapse
|